Two HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) vorinostat and romidepsin, have been FDA approved for the treatment of CTCL. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.